{"id":"W4281764145","doi":"10.1200/jco.2022.40.16_suppl.tps9137","title":"Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Trastuzumab; KRAS; Metastatic breast cancer; Phases of clinical research; Cancer; Lung cancer; Clinical trial; Breast cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01144098,0.0004870117,0.003778013,0.0004995962,0.0003733144,0.00007961785,0.0008454737,0.0001365182,0.001894327],"category_scores_gemma":[0.01134544,0.000303319,0.0002724211,0.0009796162,0.0002512277,0.0003159233,0.0004455522,0.002059172,0.000006717717],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.003982935,"about_ca_system_score_gemma":0.01975006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002526664,"about_ca_topic_score_gemma":0.0130186,"domain_scores_codex":[0.9878836,0.004103699,0.004572801,0.0007796999,0.001808477,0.0008517576],"domain_scores_gemma":[0.9802392,0.0141571,0.0029036,0.0005276387,0.00122553,0.0009469363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7153946,0.06462712,0.0599141,0.0002522789,0.0015682,0.004458996,0.001686944,0.01391529,0.00005057495,7.027214e-7,0.00013017,0.138001],"study_design_scores_gemma":[0.7399327,0.2273181,0.004396537,0.0006803905,0.002502507,0.0000963129,0.002312896,0.02109152,0.00003418074,0.00001147231,0.001328518,0.0002948284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846215,0.0008883552,0.0008526207,0.001584557,0.0008849748,0.01079766,0.00006568087,0.000018565,0.0002861235],"genre_scores_gemma":[0.9750482,0.0007618559,0.01884325,0.00082627,0.0003096525,0.002595898,0.0000284414,0.0001154988,0.001470874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.162691,"threshold_uncertainty_score":0.9999419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2405047673885687,"score_gpt":0.5669676579238045,"score_spread":0.3264628905352358,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}